Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AMPC, a powerful and efficient inhibitor of TFF3, demonstrates inhibitory effects on cell proliferation, survival, oncogenicity, and CSC-like behavior in TFF3-positive CMS4 CRC cells. It acts as a promising standalone anti-cancer agent and also enhances the effects of 5-FU when used in combination, making it a valuable tool for cancer research.
产品描述 | AMPC, a powerful and efficient inhibitor of TFF3, demonstrates inhibitory effects on cell proliferation, survival, oncogenicity, and CSC-like behavior in TFF3-positive CMS4 CRC cells. It acts as a promising standalone anti-cancer agent and also enhances the effects of 5-FU when used in combination, making it a valuable tool for cancer research. |
体外活性 |
AMPC decreases cell proliferation in CMS4 CRC cells, the IC 50 values are 2.63 μM, 4.65 μM, and 69.69 μM, respectively in SW620 (high TFF3 expression), Caco-2, SW480 cells (low TFF3 expression), respectively[1]. AMPC (1-10 μM) significantly reduces the total cellular levels of TFF3 in SW620 and Caco2 cells in a dose dependent manner[1].AMPC induces apoptosis in a dose dependent manner by the inhibition of TFF3, it induces a decrease in the S-phase population and increases caspase3/7 activity compared with control cells[1]. |
体内活性 |
AMPC (intraperitoneal injection; 40 mg/kg; once daily) leads to a significant reduction of tumour volume in AMPC-treated mice as compared to vehicle-treated mice from day 11 onward. AMPC results in larger areas of tumour necrosis and increased area of cells with apoptotic features in SW620 tumours. AMPC also significantly reduces tumour and serum TFF3 levels in vivo . Animal Model: SW620 cells are subcutaneously injected into nude mice[1]Dosage: 40 mg/kg Administration: Intraperitoneal injection; 40 mg/kg; once daily Result: Lead to tumor decrease in vivo . Results in a marked reduction of Ki67 expression in tumor. |
分子量 | 425.419 |
分子式 | C25H16FN3O3 |
CAS No. | 2254434-33-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AMPC 2254434-33-6 Inhibitor inhibitor inhibit